STAAR Surgical (NASDAQ:STAA – Get Rating) had its target price cut by Jefferies Financial Group from $165.00 to $125.00 in a research report released on Thursday morning, The Fly reports.
A number of other equities analysts also recently weighed in on the company. BTIG Research upped their target price on STAAR Surgical from $98.00 to $103.00 in a report on Thursday. Canaccord Genuity Group upped their target price on STAAR Surgical from $81.00 to $89.00 and gave the company a buy rating in a report on Tuesday, April 26th. Canaccord Genuity Group upped their target price on STAAR Surgical from $81.00 to $89.00 and gave the company a buy rating in a report on Tuesday, April 26th. Benchmark increased their price objective on STAAR Surgical from $97.00 to $117.00 and gave the stock a buy rating in a report on Thursday. Finally, Needham & Company LLC increased their price objective on STAAR Surgical from $87.00 to $110.00 and gave the stock a buy rating in a report on Thursday. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, STAAR Surgical presently has an average rating of Moderate Buy and an average target price of $106.83.
Get STAAR Surgical alerts:STAAR Surgical Trading Up 9.4 %
NASDAQ STAA opened at $111.58 on Thursday. The stock's 50-day moving average price is $75.73 and its two-hundred day moving average price is $70.75. The company has a market cap of $5.33 billion, a PE ratio of 166.54 and a beta of 1.09. STAAR Surgical has a 1 year low of $49.03 and a 1 year high of $163.08.
STAAR Surgical (NASDAQ:STAA – Get Rating) last posted its quarterly earnings data on Wednesday, August 10th. The medical instruments supplier reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.02. The firm had revenue of $81.10 million for the quarter, compared to the consensus estimate of $80.12 million. STAAR Surgical had a return on equity of 13.99% and a net margin of 12.84%. The business's revenue for the quarter was up 30.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.19 EPS. Research analysts forecast that STAAR Surgical will post 0.65 EPS for the current fiscal year.Insiders Place Their Bets
In other STAAR Surgical news, CEO Caren L. Mason sold 35,000 shares of the company's stock in a transaction that occurred on Thursday, May 19th. The stock was sold at an average price of $57.49, for a total transaction of $2,012,150.00. Following the completion of the sale, the chief executive officer now owns 83,645 shares of the company's stock, valued at $4,808,751.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 2.60% of the company's stock.
Institutional Investors Weigh In On STAAR Surgical
Large investors have recently added to or reduced their stakes in the stock. Allegheny Financial Group LTD bought a new stake in STAAR Surgical during the fourth quarter worth approximately $25,000. Rise Advisors LLC bought a new stake in STAAR Surgical during the fourth quarter worth approximately $25,000. Covestor Ltd bought a new stake in shares of STAAR Surgical in the fourth quarter valued at approximately $39,000. Lazard Asset Management LLC boosted its position in shares of STAAR Surgical by 131.1% in the first quarter. Lazard Asset Management LLC now owns 684 shares of the medical instruments supplier's stock valued at $54,000 after acquiring an additional 388 shares during the period. Finally, UBS Group AG boosted its position in shares of STAAR Surgical by 130.7% in the second quarter. UBS Group AG now owns 805 shares of the medical instruments supplier's stock valued at $57,000 after acquiring an additional 456 shares during the period. Institutional investors own 89.93% of the company's stock.
STAAR Surgical Company Profile
(Get Rating)
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.
Recommended Stories
- Get a free copy of the StockNews.com research report on STAAR Surgical (STAA)
- Here is a Simple 4 Stock Portfolio that Can Outperform the Market
- Is AMC Entertainment Pulling a Fast One on the APEs?
- Here's How the Inflation Reduction Act Energizes Power Stock
- 2 Important Retail Stock Battles to Watch
- MarketBeat: Week in Review 8/8 – 8/12
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.